Compile Data Set for Download or QSAR
maximum 50k data
Found 118 Enz. Inhib. hit(s) with all data for entry = 8328
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 17 | US9409917, 18)
Affinity DataIC50:  1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241725(US9409917, 22)
Affinity DataIC50:  1.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 17 | US9409917, 18)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  1.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241727(US9409917, 24 | US9409917, 25)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241743(US9409917, 40)
Affinity DataIC50:  2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  2.90nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241715(US9409917, 12)
Affinity DataIC50:  3.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241782(US9409917, 79 | US9409917, 80)
Affinity DataIC50:  4.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241714(US9409917, 11)
Affinity DataIC50:  4.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241804(US9409917, 101 | US9409917, 102 | US9409917, 109 |...)
Affinity DataIC50:  5.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241754(US9409917, 51)
Affinity DataIC50:  5.60nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241722(US9409917, 19)
Affinity DataIC50:  6.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241770(US9409917, 67)
Affinity DataIC50:  7.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241814(US9409917, 111 | US9409917, 112)
Affinity DataIC50:  9.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  9.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241737(US9409917, 34)
Affinity DataIC50:  10.7nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241804(US9409917, 101 | US9409917, 102 | US9409917, 109 |...)
Affinity DataIC50:  11nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241796(US9409917, 93)
Affinity DataIC50:  11.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241742(US9409917, 39)
Affinity DataIC50:  11.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241726(US9409917, 23)
Affinity DataIC50:  12.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241817(US9409917, 114)
Affinity DataIC50:  12.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241719(US9409917, 16)
Affinity DataIC50:  12.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241724(US9409917, 21)
Affinity DataIC50:  12.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241771(US9409917, 68)
Affinity DataIC50:  13.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241775(US9409917, 72)
Affinity DataIC50:  14.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241734(US9409917, 31)
Affinity DataIC50:  16nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241744(US9409917, 41)
Affinity DataIC50:  16.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  18.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 3 | US9409917, 4 | US9409917, 96 | US94...)
Affinity DataIC50:  20nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241776(US9409917, 73)
Affinity DataIC50:  20.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 104 | US9409917, 105 | US9409917, 76 | ...)
Affinity DataIC50:  20.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 59 | US9409917, 60 | US9409917, 81 | US...)
Affinity DataIC50:  20.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241735(US9409917, 32)
Affinity DataIC50:  25nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241729(US9409917, 26)
Affinity DataIC50:  25.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241757(US9409917, 54)
Affinity DataIC50:  25.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 59 | US9409917, 60 | US9409917, 81 | US...)
Affinity DataIC50:  29nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241777(US9409917, 74 | US9409917, 75)
Affinity DataIC50:  35.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241818(US9409917, 115)
Affinity DataIC50:  35.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241816(US9409917, 113)
Affinity DataIC50:  35.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241773(US9409917, 70 | US9409917, 71)
Affinity DataIC50:  36.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241748(US9409917, 45)
Affinity DataIC50:  37.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241727(US9409917, 24 | US9409917, 25)
Affinity DataIC50:  39.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241758(US9409917, 55)
Affinity DataIC50:  41.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241745(US9409917, 42)
Affinity DataIC50:  46.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241765(US9409917, 62)
Affinity DataIC50:  46.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetP2X purinoceptor 7(Homo sapiens (Human))
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241782(US9409917, 79 | US9409917, 80)
Affinity DataIC50:  51.1nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 118 total ) | Next | Last >>
Jump to: